The ACAP1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte cell line. By targeting the ACAP1 gene with CRISPR/Cas9, this product provides a heterogeneous loss-of-function model with disrupted ACAP1 expression. The polyclonal pool preserves genetic diversity, minimizing clonal artifacts and enabling robust analysis of ACAP1-dependent phenotypes in a T-cell context.
The parental Jurkat cell line, an immortalized human T-cell leukemia line, was originally isolated from peripheral blood of a 14-year-old male with T-cell leukemia. The widely utilized E6-1 clone is known for its well-characterized T-cell receptor signaling, calcium flux, and apoptotic pathways. As a suspension cell line, Jurkat cells are amenable to large-scale culture and genetic manipulation, making them a preferred model for studying T-cell biology, signal transduction, and hematological malignancies.
ACAP1 (ArfGAP with Coiled-coil, Ankyrin Repeat and PH domains 1) is a GTPase-activating protein for the small GTPase ARF6, which regulates endosomal trafficking and actin remodeling. ACAP1 is activated by ARF6-GTP and phosphoinositides, acting downstream of receptor tyrosine kinases such as EGFR. It catalyzes GTP hydrolysis on ARF6, converting it to the inactive GDP-bound state. This activity is critical for recycling integrin beta1 from endosomes to the plasma membrane, requiring interactions with clathrin adaptor AP-2 and the endosomal small GTPase RAB11. Through these interactions, ACAP1 links membrane trafficking to actin polymerization, modulating cell adhesion, spreading, and migration.
Within Jurkat T lymphocytes, ACAP1-regulated integrin recycling influences T-cell adhesion, immune synapse assembly, and migration. Disruption of ACAP1 in these polyclonal knockout cells allows dissection of ARF6-dependent trafficking in T-cell signaling and apoptosis. As Jurkat cells originate from a T-cell leukemia, this model is particularly valuable for investigating mechanisms of cancer cell invasion and immune dysregulation. The loss of ACAP1 may reveal alterations in actin dynamics and integrin surface expression, providing a tool to study how malignant T cells interact with their microenvironment.
These polyclonal knockout cells are suitable for diverse functional assays. Integrin recycling can be quantified using antibody-feeding protocols combined with flow cytometry to measure surface integrin beta1 levels. Cell migration is assessed through Transwell assays, while ARF6 activation is determined by GTP-pulldown experiments. Co-immunoprecipitation can confirm ACAP1 interactions with RAB11 or AP-2. Western blotting validates knockout efficiency, and immunofluorescence microscopy reveals endosomal localization. This model supports studies in endosomal biology, cancer metastasis, and T-cell immunology. For additional technical information, please contact Ascent Research.
